ABOUT
PH1

Primary hyperoxaluria type 1 (PH1) is a rare, progressive, and life-threatening disease1,2

Image
Image

Oxalate is continuously overproduced in PH15,6

Mutations in the alanine glyoxylate aminotransferase (AGXT) gene impair the function of the liver enzyme alanine:glyoxylate aminotransferase (AGT).1,6

PH1: a metabolic defect in the liver leads to oxalate overproduction1,6

Image
  • AGT function is impaired1,6
  • Oxalate is continuously overproduced as a result5,6

 

 

Excess oxalate damages the kidneys1,3

  • Oxalate forms calcium oxalate crystals1,3
  • Crystals can form stones or be deposited into the kidneys, leading to nephrocalcinosis1,3

PH1 is the most common type of PH and is frequently underdiagnosed, especially in adults2,3

Image

Diagnostic Delays can lead to life-threatening complications7,8

Image

5.5 Years9the median delay between clinical onset and diagnosis in adults

Image

Up to 50% of adults are diagnosed following progression to end-stage kidney disease (ESKD)10

Image

~ 10% of diagnoses are made after a kidney transplantation, upon recurrence of clinical manifestations10

Recognize PH1 when you see it

Knowing the signs and symptoms of primary hyperoxaluria type 1 (PH1) is the first step to making a diagnosis.

Clinical manifestations are a result of continuous oxalate overproduction3,4:

Signs and Symptoms of PH1*

Image

Kidney stones (nephrolithiasis) Recurrent, multiple, bilateral, and/or large stones in adults, or any stone in children. Not all patients with PH1 are stone formers; however, kidney stones are the most common symptoms.1,3,4,10

Image

NephrocalcinosisDiffuse calcification in the renal parenchyma.1,3,4,10

Image

Impaired kidney function Progressive decline toward end-stage kidney disease.†,3,4

Image

Systemic oxalosis Deposition of oxalate in various extrarenal tissues can occur as kidney function declines.3,10

Image

Failure to thrive (pediatrics only)Impaired physical growth in infancy or early childhood, often as a result of impaired kidney function.10

These are not all the signs and symptoms of PH1, and not all patients exhibit them at the same time.

Estimated glomerular filtration rate (eGFR) below 30-40ml/min/1.73m².

Severe complications may occur when the kidneys become unable to effectively excrete oxalate*,†,1,2

Systemic oxalosis may lead to the following11:

Image

BONE
DISORDERS

Image

CUTANEOUS
AND VASCULAR
MANIFESTATIONS

Image

CARDIAC
MANIFESTATIONS

Image

OPTHALMOLOGIC
MANIFESTATIONS

Image

NEUROLOGIC
MANIFESTATIONS

Typically starting at chronic kidney disease stage 3b; eGFR 30-45 mL/min/1.73 m2

These are not all the possible complications that may occur.

Metabolic and genetic testing may help with diagnosing PH16:

The AUA guidelines and literature suggest these common methods of testing:

Image
Image
Image

AUA, American Urological Association; UOx, urinary oxalate.

* In adults without bowel dysfunction.14

This testing information is provided for educational and reference purposes only. It is not intended to replace the independent medical judgment of any healthcare professional.

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s always more to learn about PH1

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist™ Logo

Alnylam Assist™ provides support services for your patients throughout their treatment with OXLUMO.

Alnylam Assist™ includes patient services in key areas, including understanding insurance benefits and financial assistance options, helping ensure access to therapy, and providing PH1 disease education.

Let's Get Started

1. Milliner DS, Harris PC, Sas DJ, et al. GeneReviews®. University of Washington, Seattle; 1993-2022. 2. Hopp K, Cogal AG, Bergstralh EJ, et al. J Am Soc Nephrol. 2015;26(10):2559-2570. 3. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271. 4. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 5. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 6. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736. 7. Bhasin B, Ürekli HM, Atta MG. World J Nephrol. 2015;4(2):235-244. 8. El-Reshaid K, Al-Bader D, Madda JP. Saudi J Kidney Dis Transpl. 2016;27(3):606-609. 9. van der Hoeven SM, van Woerden CS, Groothoff JW. Nephrol Dial Transplant. 2012;27(10):3855-3862. 10. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 11. Garrelfs SF, Oosterveld MJ, Hulton S, et al. Ped Nephrol. 2017;32:1643-1834. doi:10.1007/s00467-017-3753-x. 12. Zhao F, Bergstralh EJ, Mehta RA, et al. Clin J Am Soc Nephrol. 2016;11(1):119-126. 13. Mayo Clinic Laboratories. Accessed January 6, 2023. https://www.mayocliniclabs.com/test-catalog/download-setup.php?format=pdf&unit_code=606472 14. Pearle MS, Goldfarb DS, Assimos DG, et al. J Urol. 2014;192(2):316-324. 15. OXLUMO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.